Free Newsletter
FDA approves Watson's pain patch
Free newsletter via e-mail
Tools
Succeeding where others failed, Watson Pharmaceuticals got the FDA go-ahead to sell a generic version of Johnson & Johnson's Duragesic pain patch. With the patch, Watson will be jumping into a $1.2 billion market now divided among Duragesic and several other generic competitors.
- check out the release on the approval
Related Articles:
Watson to pay $1.9B for Andrx. Report
Bisaro handed reigns at Watson. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: